(Generic versions may still be available.)
Given the likelihood that a substantial proportion of patients exposed chronically to neuroleptics will develop tardive dyskinesia, it is advised that all patients in whom chronic use is contemplated be given, if possible, full information about this risk. The decision to inform patients and/or their guardians must obviously take into account the clinical circumstances and the competency of the patient to understand the information provided.
In manic-depressive psychosis, depressed patients may experience a shift toward the manic phase if they are treated with an antidepressant drug. Patients with paranoid symptomatology may have an exaggeration of such symptoms. The tranquilizing effect of ETRAFON (perphenazine and amitriptyline) Tablets has seemed to reduce the likelihood of this effect.
Both elevation and lowering of blood sugar levels have been reported.
The usefulness of amitriptyline in the treatment of depression has been amply demonstrated; however, it should be realized that abuse of amitriptyline among a narcotic-dependent population is not uncommon.
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Etrafon Information
Etrafon - User Reviews
Etrafon User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips on therapy and treatment.